A potential for the use of propolis in preventive and therapeutic purposes has been acknowledged, but little attention has been paid to estimation of possible propolis cytotoxicity with respect to astrocytes. We tried to estimate how a propolis ethanol extract (PEE) affects rat brain astrocytes in vitro and also to uncover crucial molecular targets of the PEE action. Primary astrocytes were exposed to PEE in doses of 10, 25, or 100 μg/ml for 24 h, and then the cell viability was monitored by MTT assay. Levels of glial fibrillary acidic protein (GFAP), transcriptional nuclear factor-κB (NF-κB), poly(ADPribose) polymerase (PARP), and angiostatins were measured using Western blot to identify the molecular mechanisms underlying cell responses to PEE. The PEE treatment exerted a dose-dependent cytotoxic effect on cultured astrocytes. The PEE modulated astrocyte signaling pathways through inducing the expression of NF-κB and PARP. At the same time, the PEE stimulated GFAP synthesis and fibrillogenesis, which was indicative for activation of astrocytes preceding their suppression. The PEE significantly increased the production of angiostatin isoforms by astrocytes, thus contributing to an antiangiogenic potential of these cells. In summary, our results indicated that exposure to the PEE exerts certain cytotoxic effects on astrocytes in a dose-dependent manner; these effects are realized through modulation of cytoskeleton rearrangements and pro-apoptotic signaling pathways. A widely available, safe, and inexpensive substance, propolis, and its components and derivatives may be used in the prevention and treatment of neuronal impairments, including malignant tumors and neurodegenerative disorders associated with excessive astrocytic activation.
Similar content being viewed by others
References
S. Huang, C. P. Zhang, K. Wang, et al., “Recent advances in the chemical composition of propolis,” Molecules, 19, No. 12, 19610-19632 (2014).
K. Sorkun, B. Süer, and B. Salih, “Determination of chemical composition of Turkish propolis,” Z. Naturforsch. Ser. C., 56, Nos. 7/8, 666-668 (2001).
A. K. Kuropatnicki, E. Szliszka, and W. Krol, “Historical aspects of propolis research in modern times,” Evid. Based Complem. Altern. Med., 2013, 964149 (2013).
N. Zabaiou, A. Fouache, A. Trousson, et al., “Biological properties of propolis extracts: something new from an ancient product,” Chem. Phys. Lipids., 17, 30025-30027 (2017).
J. M. Sforcin, “Biological properties and therapeutic applications of propolis,” Phytother. Res., 30, No. 6, 894-905 (2016).
A. P. Tiveron, P. L. Rosalen, M. Franchin, et al., “Chemical characterization and antioxidant, antimicrobial, and anti-inflammatory activities of South Brazilian organic propolis,” PLoS One, 11, No. 11, e0165588 (2016).
L. Kubiliene, V. Laugaliene, A. Pavilonis, et al., “Alternative preparation of propolis extracts: comparison of their composition and biological activities,” BMC Complem. Altern. Med., 15, 156 (2015).
T. Farooqui and A. A. Farooqui, “Beneficial effects of propolis on human health and neurological diseases,” Front. Biosci. (Elite Ed.)., 4, 779-793 (2012).
M. Shimazawa, S. Chikamatsu, N. Morimoto, et al., “Neuroprotection by Brazilian green propolis against in vitro and in vivo ischemic neuronal damage,” Evid. Based Complem. Altern. Med., 2, No. 2, 201-207 (2005).
S. Nanaware, M. Shelar, A. Sinnathambi, et al., “Neuroprotective effect of Indian propolis in β-amyloid induced memory deficit: impact on behavioral and biochemical parameters in rats,” Biomed. Pharmacother., 93, 543-553 (2017).
A. Verkhratsky, R. Zorec, and V. Parpura, “Stratification of astrocytes in healthy and diseased brain,” Brain Pathol., 27, No. 5, 629-644 (2017).
A. A. Tykhomyrov, A. S. Pavlova, and V. S. Nedzvetsky, “Glial fibrillary acidic protein (GFAP): on the 45th anniversary of discovery,” Neurophysiology, 48, No. 1, 54-71 (2016).
J. E. Burda and M. V. Sofroniew, “Reactive gliosis and the multicellular response to CNS damage and disease,” Neuron, 81, No. 2, 229-248 (2014).
W. W. Chen, X. Zhang, and W. J. Huang, “Role of neuroinflammation in neurodegenerative diseases (review),” Mol. Med. Rep., 13, No. 4, 3391-3396 (2016).
Q. Du, C. Hao, J. Gou, et al., “Protective effects of p-nitrocaffeic acid phenethyl ester on acute myocardial ischemia-reperfusion injury in rats,” Exp. Ther. Med., 11, No. 4, 1433-1440 (2016).
T. Lawrence, “The nuclear factor NF-kappaB pathway in inflammation,” Cold Spring Harb. Perspect. Biol., 1, No. 6, a001651 (2009).
F. Yuan, Z. M. Xu, L. Y. Lu, et al., “SIRT2 inhibition exacerbates neuroinflammation and blood-brain barrier disruption in experimental traumatic brain injury by enhancing NF-κB p65 acetylation and activation,” J. Neurochem., 136, No. 3, 581-593 (2016).
M. O. Hottiger, P. O. Hassa, B. Lüscher, et al., “Toward a unified nomenclature for mammalian ADPribosyltransferases,” Trends Biochem. Sci., 35, No. 4, 208-219 (2010).
B. A. Gibson and L. W. Kraus, “New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs,” Nat. Rev. Mol. Cell Biol., 13, 411-424 (2012).
S. Vyas and P. Chang, “New PARP targets for cancer therapy,” Nat. Rev. Cancer, 14, 502-509 (2014).
V. Berezowski, A. M. Fukuda, R. Cecchelli, and J. Badaut, “Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology,” Int. J. Cell. Biol., 2012, 176287 (2012).
A. A. Tykhomyrov, V. S. Nedzvetsky, C. A. Ağca, et al., “Plasminogen and its fragments in rat brain: a plausible role for astrocytes in angiostatin generation,” Ukr. Biochem. J., 89, No. 2, 43-54 (2017).
M. L. Wahl, D. J. Kenan, M. Gonzalez-Gronow, and S. V. Pizzo, “Angiostatin’s molecular mechanism: aspects of specificity and regulation elucidated,” J. Cell. Biochem., 96, No. 2, 242-261 (2005).
A. A. Tykhomyrov, S. I. Shram, and T. V. Grinenko, “Role of angiostatins in diabetic complications,” Biomed. Khim., 61, No. 1, 41-56 (2015).
J. K. Ryu, J. P. Little, and A. Klegeris, “Actions of the anti-angiogenic compound angiostatin in an animal model of Alzheimer’s disease,” Curr. Alzheimer Res., 10, No. 3, 252-260 (2013).
J. Carmichael, W. G. DeGraff, A. F. Gazdar, et al., “Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing,” Cancer Res., 47, No. 4, 936-942 (1987).
H. Xuan, J. Zhao, J. Miao, et al., “Effect of Brazilian propolis on human umbilical vein endothelial cell apoptosis,” Food Chem. Toxicol., 49, No. 1, 78-85 (2011).
M. M. Guzyk, A. A. Tykhomyrov, V. S. Nedzvetsky, et al., “Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors reduce reactive gliosis and improve angiostatin levels in retina of diabetic rats,” Neurochem. Res., 41, No. 10, 2526-2537 (2016).
M. M. Bradford, “Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Anal. Biochem., 72, 248-254 (1976).
V. Bankova, “Chemical diversity of propolis and the problem of standardization,” J. Ethnopharmacol., 100, Nos. 1/2, 114-117 (2005).
S. Kumazawa, T. Hamasaka, and T. Nakayama, “Antioxidant activity of propolis of various geographic origins,” Food Chem., 84, No. 3, 329-339 (2004).
M. A. E. Watamnabe, M. K. Amarante, B. J. Conti, and J. M. Sforcin, “Cytotoxic constituents of propolis inducing anticancer effects: a review,” J. Pharm. Pharmacol., 63, 1378-1386 (2011).
M. Tartik, E. Darendelioglu, G. Aykutoglu, and G. Baydas, “Turkish propolis supresses MCF-7 cell death induced by homocysteine,” Biomed. Pharmacother., 82, 704-712 (2016).
G. Murtaza, S. Karim, and M. R. Akram, “Caffeic acid phenethyl ester and therapeutic potentials,” Biomed. Res. Int., 2014, 145342 (2014).
R. Markiewicz-Żukowska, H. Car, S. K. Naliwajko, et al., “Ethanolic extract of propolis, chrysin, CAPE inhibit human astroglia cells,” Adv. Med. Sci., 57, No. 2, 208-216 (2012).
C. N. Chen, C. L. Wu, and J. K. Lin, “Apoptosis of human melanoma cells induced by the novel compounds propolin A and propolin B from Taiwenese propolis,” Cancer Lett., 245, Nos. 1/2, 218-231 (2007).
M. Kumazaki, H. Shinohara, and K. Taniguchi, “Propolis cinnamic acid derivatives induce apoptosis through both extrinsic and intrinsic apoptosis signaling pathways and modulate of miRNA expression,” Phytomedicine, 21, Nos. 8/9, 1070-1077 (2014).
M. Schieber and N. S. Chandel, “ROS function in redox signaling and oxidative stress,” Curr. Biol., 24, No. 10, R453-R462 (2014).
R. A. de Sá, F. A. de Castro, E. C. Eleutherio, et al., “Brazilian propolis protects Saccharomyces cerevisiae cells against oxidative stress,” Braz. J. Microbiol., 44, No. 3, 993-1000 (2013).
R. C. Calhelha, S. Falcão, M. J. Queiroz, et al., “Cytotoxicity of Portuguese propolis: the proximity of the in vitro doses for tumor and normal cell lines,” Biomed. Res. Int., 2014, 897361 (2014).
L. M. da Silva, Y. Frión-Herrera, A. R. Bartolomeu, et al., “Mechanisms involved in the cytotoxic action of Brazilian propolis and caffeic acid against HEp-2 cells and modulation of P-glycoprotein activity,” J. Pharm. Pharmacol., doi: https://doi.org/10.1111/jphp.12789 (2017).
X. M. Zhang and J. Zhu, “Kainic acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines,” Current Neuropharmacol., 9, No. 2, 388-398 (2011).
H. Y. Hsiao, Y. C. Chen, H. M. Chen, et al., “A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington’s disease,” Human Mol. Genet., 22, No. 9, 1826-1842 (2013).
R. Saggu, T. Schumacher, and F. Gerich, “Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia,” Acta Neuropathol. Commun., 4, No. 1, 76 (2016).
B. J. Conti, K. B. Santiago, E. O. Cardoso, et al., “Propolis modulates miRNAs involved in TLR-4 pathway, NF-κB activation, cytokine production and in the bactericidal activity of human dendritic cells,” J. Pharm. Pharmacol., 68, No. 12, 1604-1612 (2016).
C. C. Alano, P. Garnier, W. Ying, et al., “NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death,” J. Neurosci., 30, No. 8, 2967-2978 (2010).
G. V. Chaitanya, A. J. Steven, and P. P. Babu, “PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration,” Cell. Commun. Signal., 8, 31 (2010).
N. J. Abbott, L. Rönnbäck, and E. Hansson, “Astrocyteendothelial interactions at the blood-brain barrier,” Nat. Rev. Neurosci., 7, No. 1, 41-53 (2006).
J. M. Cherrington, L. M. Strawn, and L. K. Shawver, “New paradigms for the treatment of cancer: the role of anti-angiogenesis agents,” Adv. Cancer Res., 79, 1-38 (2000).
W. Y. Kim and H. Y. Lee, “Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors,” FEBS J., 276, No. 17, 4653-4664 (2009).
W. C. Sin, Q. Aftab, J. F. Bechberger, et al., “Astrocytes promote glioma invasion via the gap junction protein connexin43,” Oncogene, 35, No. 12, 1504-1516 (2016).
D. M. Le, A. Besson, D. K. Fogg, et al., “Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade,” J. Neurosci., 23, No. 10, 4034-4043 (2003).
A. Briens, I. Bardou, H. Lebas, et al., “Astrocytes regulate the balance between plasminogen activation and plasmin clearance via cell-surface actin,” Cell Discov., 3, 17001 (2017).
M. J. O’Mullane and M. S. Baker, “Elevated plasminogen receptor expression occurs as a degradative phase event in cellular apoptosis,” Immunol. Cell Biol., 77, No. 3, 249-255 (1999).
Y. N. Li, R. Pan, X. J. Qin, et al., “Ischemic neurons activate astrocytes to disrupt endothelial barrier via increasing VEGF expression,” J. Neurochem., 129, No. 1, 120-129 (2014).
H. Izuta, M. Shimazawa, K. Tsuruma, et al., “Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells,” BMC Complem. Altern. Med., 9, 45 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Agca, C.A., Tykhomyrov, A.A., Baydas, G. et al. Effects of a Propolis Extract on the Viability of and Levels of Cytoskeletal and Regulatory Proteins in Rat Brain Astrocytes: an In Vitro Study. Neurophysiology 49, 261–271 (2017). https://doi.org/10.1007/s11062-017-9680-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11062-017-9680-4